Clinical Trial Update: Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imiquimod for HPV-related vulvar intraepithelial neoplasia (VIN 2/3) and anogenital warts has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Warts
• Human Papillomavirus Infection
• Vulvar Intraepithelial Neoplasia

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: Medical University of Vienna | Conditions: HPV | Phase 2 | Status: COMPLETED